Your browser is no longer supported. Please, upgrade your browser.
Settings
ADRO Aduro BioTech, Inc. daily Stock Chart
ADRO [NASD]
Aduro BioTech, Inc.
Index- P/E- EPS (ttm)-1.17 Insider Own1.00% Shs Outstand81.02M Perf Week-4.86%
Market Cap554.99M Forward P/E- EPS next Y-1.07 Insider Trans-19.87% Shs Float41.55M Perf Month-13.29%
Income-88.10M PEG- EPS next Q-0.32 Inst Own47.20% Short Float15.77% Perf Quarter-8.05%
Sales20.10M P/S27.61 EPS this Y13.20% Inst Trans0.05% Short Ratio16.47 Perf Half Y1.48%
Book/sh2.53 P/B2.71 EPS next Y15.70% ROA-20.40% Target Price15.13 Perf Year-47.71%
Cash/sh3.79 P/C1.81 EPS next 5Y-1.10% ROE-38.60% 52W Range5.82 - 14.05 Perf YTD-8.67%
Dividend- P/FCF- EPS past 5Y-52.30% ROI-38.60% 52W High-51.25% Beta-
Dividend %- Quick Ratio9.10 Sales past 5Y126.40% Gross Margin- 52W Low17.60% ATR0.40
Employees156 Current Ratio9.10 Sales Q/Q73.70% Oper. Margin- RSI (14)39.26 Volatility4.27% 5.81%
OptionableYes Debt/Eq0.00 EPS Q/Q13.70% Profit Margin- Rel Volume1.30 Prev Close6.95
ShortableYes LT Debt/Eq0.00 EarningsAug 01 BMO Payout- Avg Volume397.95K Price6.85
Recom1.80 SMA20-7.87% SMA50-10.36% SMA200-13.31% Volume517,479 Change-1.44%
Feb-22-18Initiated Cantor Fitzgerald Overweight $15
Dec-13-17Reiterated H.C. Wainwright Buy $18 → $9.50
May-01-17Initiated Rodman & Renshaw Buy $18
May-17-16Reiterated FBR Capital Outperform $30 → $22
Mar-15-16Downgrade BofA/Merrill Buy → Underperform $32 → $14
Mar-02-16Initiated FBR Capital Outperform $30
Dec-01-15Downgrade Oppenheimer Outperform → Perform
Nov-24-15Reiterated ROTH Capital Buy $74 → $68
Oct-20-15Initiated Oppenheimer Outperform $30
May-11-15Initiated Leerink Partners Outperform $48
May-11-15Initiated Canaccord Genuity Buy $43
May-11-15Initiated BofA/Merrill Buy $40
Apr-20-15Initiated ROTH Capital Buy $74
Jun-29-18 07:45AM  Report: Developing Opportunities within Newfield Exploration, Heritage Insurance, AptarGroup, Alder BioPharmaceuticals, TrueCar, and Aduro Biotech Future Expectations, Projections Moving into 2018 GlobeNewswire
Jun-07-18 04:01PM  Aduro Biotech Announces Initiation of Phase 1b Clinical Trial in Non-Small Cell Lung Cancer under Janssen Strategic Partnership for ADU-214 in Combination with Nivolumab GlobeNewswire
07:45AM  Complimentary Technical Snapshots on Adverum Biotechnologies and Three More Biotech Stocks ACCESSWIRE
Jun-01-18 10:48AM  Why is Aduro (ADRO) Up 18.6% Since Its Last Earnings Report? Zacks
May-17-18 08:00AM  Detailed Research: Economic Perspectives on Churchill Downs, Nordic American Tankers, News Corporation, Aduro Biotech, MannKind, and Crane What Drives Growth in Today's Competitive Landscape GlobeNewswire
May-10-18 04:01PM  Aduro Biotech to Present at the Bank of America Merrill Lynch 2018 Health Care Conference GlobeNewswire
May-04-18 11:56AM  Aduro (ADRO) Q1 Loss Narrower Than Expected, Revenues Beat Zacks
May-02-18 05:59PM  Aduro Biotech: 1Q Earnings Snapshot Associated Press
04:01PM  Aduro Biotech Reports First Quarter 2018 Financial Results GlobeNewswire
Apr-26-18 08:00AM  Aduro Biotech Presents Early Observations From its Personalized Neoantigen-based pLADD Therapy Clinical Study at European Neoantigen Summit GlobeNewswire
Apr-17-18 04:01PM  Aduro Biotech Highlights Preclinical Data for Three Programs Reported at the American Association for Cancer Research Annual Meeting GlobeNewswire
Apr-02-18 04:01PM  Aduro Biotech to Present at the H.C. Wainwright Annual Global Life Sciences Conference GlobeNewswire
Mar-28-18 10:39AM  Chinese investors jump into $70 million round for early-stage S.F. cancer-fighting company American City Business Journals
Mar-22-18 07:48AM  Global funds manager scores big gains with stock picks that may surprise you MarketWatch
Mar-14-18 04:31PM  Aduro Biotech Announces Upcoming Data Presentations at the 2018 American Association for Cancer Research Annual Meeting GlobeNewswire +5.11%
04:01PM  Aduro Biotech to Present at the 28th Annual Oppenheimer Healthcare Conference GlobeNewswire
Mar-07-18 04:01PM  Aduro Biotech to Present at the 38th Annual Cowen Healthcare Conference GlobeNewswire +8.03%
Mar-05-18 04:05PM  Aduro Announces Milestone Achieved under Merck Collaboration for Initiation of Anti-CD27 Phase I Trial in Advanced Solid Tumors GlobeNewswire
04:01PM  Aduro Biotech Appoints Hans van Eenennaam Executive Vice President Antibody Research and Site Head, Aduro Biotech Europe GlobeNewswire
Mar-01-18 04:51PM  Aduro Biotech reports 4Q loss Associated Press
04:01PM  Aduro Biotech Announces Fourth Quarter and Full Year 2017 Financial Results GlobeNewswire
07:35AM  Analysis: Positioning to Benefit within Penumbra, Qualys, OraSure Technologies, Air Lease, Aduro Biotech, and Progenics Pharmaceuticals Research Highlights Growth, Revenue, and Consolidated Results GlobeNewswire
Feb-08-18 04:31PM  Aduro Biotech to Present at the Leerink Partners 7th Annual Global Healthcare Conference GlobeNewswire
Jan-22-18 11:47PM  SE Asia Stocks-Most rise; Indonesia hits fresh high Reuters
Jan-05-18 08:00AM  Aduro Biotech Announces Management Changes GlobeNewswire
07:30AM  Report: Developing Opportunities within Aduro Biotech, Progenics Pharmaceuticals, Gevo, OSI, Senseonics, and Donnelley Financial Solutions Future Expectations, Projections Moving into 2018 GlobeNewswire
Jan-04-18 04:01PM  Aduro Biotech to Present at the 36th Annual J.P. Morgan Healthcare Conference GlobeNewswire +5.41%
Dec-29-17 11:26AM  ETFs with exposure to Aduro BioTech, Inc. : December 29, 2017 Capital Cube
Dec-20-17 08:00AM  Aduro Biotech Expands Leading Intellectual Property Position in STING Field with Newly Issued Patent GlobeNewswire
Dec-18-17 02:22PM  ETFs with exposure to Aduro BioTech, Inc. : December 18, 2017 Capital Cube
08:00AM  Aduro Biotech Announces the Initiation of a Phase 1/2 Clinical Trial of BION-1301, a Novel Anti-APRIL Antibody, for the Treatment of Multiple Myeloma GlobeNewswire
Dec-12-17 08:00AM  Aduro Biotech Provides Update on CRS-207 Programs GlobeNewswire +5.10%
Dec-11-17 04:01PM  Aduro Biotech to Host a Program Update Call GlobeNewswire
Dec-04-17 11:15AM  Aduro BioTech, Inc. Value Analysis (NASDAQ:ADRO) : December 4, 2017 Capital Cube -5.24%
Dec-01-17 07:13AM  Aduro BioTech, Inc. breached its 50 day moving average in a Bullish Manner : ADRO-US : December 1, 2017 Capital Cube
Nov-29-17 10:46AM  ETFs with exposure to Aduro BioTech, Inc. : November 29, 2017 Capital Cube +5.14%
Nov-21-17 01:00AM  Aduro Biotech Scientific Advisor and Co-Founder of Aduro Biotech Europe Wiebe Olijve Honored with Royal Decoration GlobeNewswire
Nov-16-17 11:04AM  ETFs with exposure to Aduro BioTech, Inc. : November 16, 2017 Capital Cube
Nov-10-17 08:00AM  Aduro Biotech Announces Promising Preclinical Data that Validate Anti-CTLA-4 Antibody ADU-1604 GlobeNewswire
Nov-06-17 06:50PM  Coal demand in Indonesia is on the upswing: executive CNBC Videos
11:00AM  ETFs with exposure to Aduro BioTech, Inc. : November 6, 2017 Capital Cube
Nov-02-17 09:15AM  Aduro BioTech, Inc. :ADRO-US: Earnings Analysis: Q3, 2017 By the Numbers : November 2, 2017 Capital Cube
Nov-01-17 09:05AM  Aduro Biotech Announces Upcoming Data Presentations at the 59th American Society of Hematology Annual Meeting GlobeNewswire -5.03%
Oct-31-17 06:26PM  Aduro Biotech reports 3Q loss Associated Press
04:01PM  Aduro Biotech Reports Third Quarter 2017 Financial Results GlobeNewswire
Oct-25-17 09:46AM  ETFs with exposure to Aduro BioTech, Inc. : October 25, 2017 Capital Cube
Oct-17-17 08:00AM  Aduro Biotech Announces Presentation of Phase 1 Data for LADD-based Immunotherapy at World Conference on Lung Cancer GlobeNewswire
Oct-09-17 08:00AM  Aduro Biotech Announces Upcoming Data Presentations at the Society for Immunotherapy of Cancers 32nd Annual Meeting GlobeNewswire
Sep-27-17 08:01AM  Aduro Biotech Announces First Patient Dosed in Phase 1 Clinical Trial of Personalized Immunotherapy pLADD Based on Proprietary Neoantigen Technology GlobeNewswire
Sep-26-17 08:01AM  Aduro Biotech Announces Advancement of ADU-S100 into Global Combination Trial With PDR001 for the Treatment of Solid Tumors and Lymphomas GlobeNewswire
Sep-18-17 04:02PM  Aduro Biotech to Present at Three Investor Conferences in the Second Half of September GlobeNewswire
Sep-08-17 02:45AM  Why Is Aduro Biotech (ADRO) Down 6.8% Since the Last Earnings Report? Zacks
Sep-07-17 12:05PM  ETFs with exposure to Aduro BioTech, Inc. : September 7, 2017 Capital Cube
Sep-06-17 08:25AM  Aduro BioTech, Inc. :ADRO-US: Earnings Analysis: Q2, 2017 By the Numbers : September 6, 2017 Capital Cube
Sep-01-17 09:56AM  Aduro BioTech, Inc. breached its 50 day moving average in a Bullish Manner : ADRO-US : September 1, 2017 Capital Cube
Aug-31-17 04:05PM  Aduro Biotech to Present at Three Investor Conferences in the First Half of September GlobeNewswire
Aug-23-17 05:09PM  Aduro BioTech, Inc. Value Analysis (NASDAQ:ADRO) : August 23, 2017 Capital Cube
Aug-11-17 10:11AM  Aduro BioTech, Inc. breached its 50 day moving average in a Bearish Manner : ADRO-US : August 11, 2017 Capital Cube
Aug-09-17 08:00AM  Aduro Biotech Bolsters Intellectual Property Position in STING Field with Two New Patents GlobeNewswire
Aug-03-17 04:08PM  Aduro (ADRO) Q2 Loss Narrower than Expected, Revenues Top Zacks -5.56%
04:05PM  Aduro Biotech to Present at the 37th Annual Canaccord Genuity Growth Conference GlobeNewswire
Aug-02-17 10:54PM  Aduro Biotech reports 2Q loss Associated Press
04:01PM  Aduro Biotech Reports Second Quarter 2017 Financial Results GlobeNewswire
Jul-27-17 08:00AM  Aduro Biotech Announces Andrea van Elsas, Ph.D., to be Named Chief Scientific Officer Effective September 1, 2017 GlobeNewswire
Jul-13-17 08:00AM  Aduro Announces Milestone Achieved Relating to Collaboration with Merck for Development of Anti-CD27 Antibody for the Treatment of Cancer GlobeNewswire
Jul-07-17 08:20AM  Verastem (VSTM) Shows Strength: Stock Adds 42% in Session Zacks
Jun-29-17 04:05PM  Aduro Biotech Announces Initiation of Phase 2 Clinical Trial of CRS-207 in Combination with KEYTRUDA® (pembrolizumab) for the Treatment of Previously-Treated Gastroesophageal Adenocarcinoma GlobeNewswire
09:47AM  Aduro Starts Phase II Combo Study with CRS-207 & Keytruda Zacks
Jun-28-17 04:05PM  Aduro Biotech Announces First Patient Dosed in Phase 2 Clinical Trial of CRS-207 in Combination with KEYTRUDA® (pembrolizumab) for the Treatment of Patients with Previously Treated Malignant Pleural Mesothelioma GlobeNewswire
Jun-14-17 08:46AM  Can Aduro BioTech (ADRO) Run Higher on Strong Earnings Estimate Revisions? Zacks
Jun-01-17 08:05AM  Aduro Biotech Announces FDA Clearance of Investigational New Drug Application to Evaluate the Combination of ADU-S100 with PDR001 for the Treatment of Solid Tumors and Lymphomas GlobeNewswire
May-26-17 07:05AM  Aduro Biotech to Host and Webcast an Investor Event in Conjunction with the 2017 ASCO Annual Meeting GlobeNewswire
May-17-17 03:18PM  Aduro Biotech, Merck Team on Cancer Drug Trial TheStreet.com
09:05AM  Aduro Biotech Announces Clinical Collaboration with Merck to Evaluate the Combination of Aduros CRS-207 with Mercks KEYTRUDA® (Pembrolizumab) for the Treatment of Mesothelioma GlobeNewswire
May-05-17 03:46PM  ETFs with exposure to Aduro BioTech, Inc. : May 5, 2017 Capital Cube
May-04-17 10:08AM  Aduro BioTech, Inc. :ADRO-US: Earnings Analysis: Q1, 2017 By the Numbers : May 4, 2017 Capital Cube
May-02-17 07:01PM  Aduro Biotech reports 1Q loss Associated Press
04:05PM  Aduro Biotech Reports First Quarter 2017 Financial Results GlobeNewswire
Apr-25-17 08:00AM  Aduro Biotech to Present at Two Investor Conferences in May GlobeNewswire
Apr-20-17 04:05PM  Aduro Biotech Announces Management Promotions GlobeNewswire
Apr-05-17 04:14PM  ETFs with exposure to Aduro BioTech, Inc. : April 5, 2017 Capital Cube
Apr-03-17 02:28AM  Why Is Aduro (ADRO) Down 3.6% Since the Last Earnings Report? Zacks -8.84%
Mar-27-17 10:00AM  Aduro Biotech, Inc. (Nasdaq: ADRO) to Ring The Nasdaq Stock Market Opening Bell GlobeNewswire
Mar-17-17 11:58AM  Aduro BioTech, Inc. :ADRO-US: Earnings Analysis: Q4, 2016 By the Numbers : March 17, 2017 Capital Cube
Mar-16-17 10:18AM  Aduro BioTech, Inc. :ADRO-US: Earnings Analysis: 2016 By the Numbers : March 16, 2017 Capital Cube
Mar-15-17 09:00AM  Aduro Biotech to Host Research and Development Day in New York GlobeNewswire
Mar-10-17 09:00AM  Aduro Biotech Awarded East Bay Innovation Award for its Contributions in Life Sciences and the San Francisco East Bay Community GlobeNewswire
Mar-08-17 01:04PM  ADURO BIOTECH, INC. Financials
Mar-06-17 04:05PM  Aduro Biotech Announces Upcoming Data Presentations at the 2017 American Association for Cancer Research Annual Meeting GlobeNewswire
Mar-03-17 08:22AM  Aduro (ADRO) Loss Wider than Expected, Sales Miss in Q4 Zacks
Mar-02-17 04:05PM  Aduro Biotech Announces Upcoming Data Presentations at the Keystone Symposia on Cancer Immunology and Immunotherapy Conference GlobeNewswire
Mar-01-17 05:27PM  Aduro Biotech reports 4Q loss
04:34PM  ADURO BIOTECH, INC. Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements and Exhib
04:27PM  ADURO BIOTECH, INC. Files SEC form 10-K, Annual Report
04:05PM  Aduro Biotech Announces Fourth Quarter and Full Year 2016 Financial Results GlobeNewswire
Feb-28-17 08:00AM  Aduro Biotech to Present at Two Investor Conferences in March GlobeNewswire
Feb-10-17 08:00AM  Aduro Biotech to Present at the Leerink Partners 6th Annual Global Healthcare Conference GlobeNewswire
Feb-01-17 07:28AM  Aduro BioTech, Inc. breached its 50 day moving average in a Bullish Manner : ADRO-US : February 1, 2017
Jan-26-17 08:00AM  Aduro Biotech Announces Appointment of Leading Immunotherapy and Oncology Experts to Scientific Advisory Board GlobeNewswire
Jan-20-17 08:39AM  Aduro (ADRO) Inks License Agreement with Stanford University
Aduro BioTech, Inc., an immunotherapy company, focuses on the discovery, development, and commercialization of therapies that transform the treatment of challenging diseases. The company is developing ADU-S100, which is in Phase I monotherapy study, as well as in Phase 1b combination study with an anti-PD1 immune checkpoint inhibitor; ADU-214 that is in Phase I clinical trials for the treatment of lung cancer; and ADU-741 for the treatment of prostate cancer. Its products pipeline also comprises BION-1301, a B-select monoclonal antibody novel therapy for multiple myeloma; A PRoliferation-Inducing Ligand for the treatment of multiple myeloma, chronic lymphocytic leukemia, and colorectal carcinoma; CD27, a co-stimulatory receptor for the treatment of cancer; and CTLA-4 for the treatment of advanced melanoma and other cancers. The company's pLADD program is based on proprietary attenuated strains of Listeria that have been engineered to express tumor neo antigens that are specific to an individual patient's tumor. It has collaboration agreements with Novartis Pharmaceuticals Corporation, Janssen Biotech, Inc, and Merck. The company was formerly known as Oncologic, Inc. and changed its name to Aduro BioTech, Inc. in June 2008. Aduro BioTech, Inc. was founded in 2000 and is based in Berkeley, California.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
ISAACS STEPHEN TPresident and CEOJun 01Option Exercise1.0040,00040,000245,746Jun 05 08:58 PM
ISAACS STEPHEN TPresident and CEOJun 01Sale8.6840,000347,004205,746Jun 05 08:58 PM
Templeman BlaineChief Legal OfficerMay 17Sale8.152,00016,30069,937May 21 06:25 PM
ISAACS STEPHEN TPresident and CEOMay 09Option Exercise0.9740,00038,976245,746May 11 05:00 PM
ISAACS STEPHEN TPresident and CEOMay 09Sale8.0140,000320,348205,746May 11 05:00 PM
ISAACS STEPHEN TPresident and CEOApr 02Option Exercise0.8240,00032,800245,746Apr 04 06:26 PM
ISAACS STEPHEN TPresident and CEOApr 02Sale8.9140,000356,400205,746Apr 04 06:26 PM
ISAACS STEPHEN TPresident and CEOMar 09Option Exercise0.5046,41723,165252,163Mar 09 07:40 PM
ISAACS STEPHEN TPresident and CEOMar 09Sale8.7746,417407,268205,746Mar 09 07:40 PM
ISAACS STEPHEN TPresident and CEOMar 08Option Exercise0.4525,63411,535231,380Mar 09 07:40 PM
ISAACS STEPHEN TPresident and CEOMar 08Sale7.9525,634203,790205,746Mar 09 07:40 PM
van Elsas AndreaChief Scientific OfficerFeb 26Sale6.486,87444,522216,669Feb 27 06:56 PM
SCHAFER GREGORY WChief Operating OfficerJan 25Option Exercise0.8260,00049,200250,745Jan 26 07:15 PM
ISAACS STEPHEN TPresident and CEOJan 05Option Exercise0.457,9493,577213,695Jan 09 05:48 PM
ISAACS STEPHEN TPresident and CEOJan 05Sale7.957,94963,195205,746Jan 09 05:48 PM
SCHAFER GREGORY WChief Operating OfficerJan 02Option Exercise1.0420,00020,767210,745Jan 03 06:59 PM
SCHAFER GREGORY WChief Operating OfficerJan 02Sale7.6120,000152,142190,745Jan 03 06:59 PM
Brockstedt Dirk G.EVP of Research and Dev.Dec 29Option Exercise1.4552,00075,400124,603Jan 03 07:03 PM
SCHAFER GREGORY WChief Operating OfficerDec 29Option Exercise0.8242,00034,440190,745Jan 03 06:59 PM
Templeman BlaineExecutive VP, General CounselDec 18Sale8.252,88423,79369,937Dec 20 06:52 PM
Brockstedt Dirk G.EVP of Research and Dev.Dec 15Option Exercise1.4564,10892,957137,826Dec 15 08:02 PM
Brockstedt Dirk G.EVP of Research and Dev.Dec 15Sale8.1165,223529,18772,603Dec 15 08:02 PM
Brockstedt Dirk G.EVP of Research and Dev.Dec 01Option Exercise0.5210,0005,20083,718Dec 04 07:59 PM
ISAACS STEPHEN TPresident and CEODec 01Option Exercise0.4540,00018,000213,921Dec 04 07:53 PM
SCHAFER GREGORY WChief Operating OfficerDec 01Option Exercise1.0420,00020,767168,745Dec 04 07:56 PM
Lew JenniferSr. Vice President of FinanceDec 01Option Exercise0.826,6005,41268,938Dec 04 07:57 PM
SCHAFER GREGORY WChief Operating OfficerDec 01Sale9.3420,000186,882148,745Dec 04 07:56 PM
ISAACS STEPHEN TPresident and CEODec 01Sale9.3840,000375,028173,921Dec 04 07:53 PM
Brockstedt Dirk G.EVP of Research and Dev.Dec 01Sale9.4010,00093,99873,718Dec 04 07:59 PM
Lew JenniferSr. Vice President of FinanceDec 01Sale9.466,60062,43362,338Dec 04 07:57 PM
Templeman BlaineExecutive VP, General CounselNov 17Sale8.852432,15158,834Nov 17 06:43 PM
Lew JenniferSr. Vice President of FinanceNov 15Option Exercise0.826,6005,41268,938Nov 17 06:42 PM
Lew JenniferSr. Vice President of FinanceNov 15Sale8.956,60059,07062,338Nov 17 06:42 PM
Brockstedt Dirk G.EVP of Research and Dev.Nov 13Option Exercise0.524,0622,11277,780Nov 14 06:09 PM
ISAACS STEPHEN TPresident and CEONov 13Option Exercise0.453,4001,530177,321Nov 14 06:20 PM
ISAACS STEPHEN TPresident and CEONov 13Sale8.003,40027,215173,921Nov 14 06:20 PM
Brockstedt Dirk G.EVP of Research and Dev.Nov 13Sale8.004,06232,49673,718Nov 14 06:09 PM
Brockstedt Dirk G.EVP of Research and Dev.Nov 10Option Exercise0.521,81594475,533Nov 14 06:09 PM
ISAACS STEPHEN TPresident and CEONov 10Option Exercise0.4516,4007,380190,321Nov 14 06:20 PM
ISAACS STEPHEN TPresident and CEONov 10Sale7.9616,400130,508173,921Nov 14 06:20 PM
Brockstedt Dirk G.EVP of Research and Dev.Nov 10Sale8.011,81514,54473,718Nov 14 06:09 PM
ISAACS STEPHEN TPresident and CEONov 07Option Exercise0.453,8001,710177,721Nov 08 07:56 PM
ISAACS STEPHEN TPresident and CEONov 07Sale7.953,80030,223173,921Nov 08 07:56 PM
ISAACS STEPHEN TPresident and CEONov 06Option Exercise0.4516,4007,380190,321Nov 08 07:56 PM
Brockstedt Dirk G.EVP of Research and Dev.Nov 06Option Exercise0.524,1232,14477,841Nov 08 07:59 PM
SCHAFER GREGORY WChief Operating OfficerNov 06Option Exercise1.0420,00020,767168,745Nov 08 08:01 PM
SCHAFER GREGORY WChief Operating OfficerNov 06Sale7.9720,000159,312148,745Nov 08 08:01 PM
Brockstedt Dirk G.EVP of Research and Dev.Nov 06Sale8.044,12333,13273,718Nov 08 07:59 PM
ISAACS STEPHEN TPresident and CEONov 06Sale7.9816,400130,934173,921Nov 08 07:56 PM
Lew JenniferSr. Vice President of FinanceOct 02Option Exercise0.826,6005,41268,938Oct 04 08:21 PM
ISAACS STEPHEN TPresident and CEOOct 02Option Exercise0.4540,00018,000213,921Oct 04 08:23 PM
SCHAFER GREGORY WChief Operating OfficerOct 02Option Exercise1.3620,00027,148168,745Oct 04 08:26 PM
Brockstedt Dirk G.EVP of Research and Dev.Oct 02Option Exercise0.5210,0005,20083,718Oct 04 08:31 PM
Brockstedt Dirk G.EVP of Research and Dev.Oct 02Sale10.5910,000105,87073,718Oct 04 08:31 PM
SCHAFER GREGORY WChief Operating OfficerOct 02Sale10.7520,000215,060148,745Oct 04 08:26 PM
ISAACS STEPHEN TPresident and CEOOct 02Sale10.7840,000431,032173,921Oct 04 08:23 PM
Lew JenniferSr. Vice President of FinanceOct 02Sale10.616,60069,99562,338Oct 04 08:21 PM
Templeman BlaineExecutive VP, General CounselSep 18Sale11.202,88432,30158,834Sep 20 07:11 PM
ISAACS STEPHEN TPresident and CEOSep 13Sale10.9912,204134,071173,921Sep 14 09:25 PM
SCHAFER GREGORY WChief Operating OfficerSep 13Sale10.994,85953,380148,745Sep 14 09:24 PM
Brockstedt Dirk G.EVP of Research and Dev.Sep 13Sale10.993,55739,07673,718Sep 14 09:22 PM
Lew JenniferSr. Vice President of FinanceSep 13Sale10.993,55739,07662,338Sep 14 09:21 PM
van Elsas AndreaChief Scientific OfficerSep 13Sale10.994,92254,072207,231Sep 14 09:20 PM
Templeman BlaineExecutive VP, General CounselSep 13Sale10.993,55739,07661,718Sep 14 09:19 PM
Brockstedt Dirk G.EVP of Research and Dev.Sep 01Option Exercise0.5210,0005,20059,300Sep 06 04:27 PM
ISAACS STEPHEN TPresident and CEOSep 01Option Exercise0.4540,00018,000144,025Sep 06 04:28 PM
Lew JenniferSr. Vice President of FinanceSep 01Option Exercise0.826,6005,41249,195Sep 06 04:29 PM
SCHAFER GREGORY WChief Operating OfficerSep 01Option Exercise1.2420,00024,800140,979Sep 06 04:30 PM
Lew JenniferSr. Vice President of FinanceSep 01Sale11.706,60077,24242,595Sep 06 04:29 PM
ISAACS STEPHEN TPresident and CEOSep 01Sale11.7140,000468,596104,025Sep 06 04:28 PM
Sacks NatalieChief Medical OfficerSep 01Sale11.714,88557,19645,115Sep 06 04:32 PM
SCHAFER GREGORY WChief Operating OfficerSep 01Sale11.7020,000233,980120,979Sep 06 04:30 PM
Brockstedt Dirk G.EVP of Research and Dev.Sep 01Sale11.6910,000116,94849,300Sep 06 04:27 PM
Dubensky Thomas W.Chief Scientific OfficerAug 11Option Exercise1.009,0889,08848,988Aug 11 08:03 PM
Dubensky Thomas W.Chief Scientific OfficerAug 11Sale11.179,088101,53839,900Aug 11 08:03 PM
Dubensky Thomas W.Chief Scientific OfficerAug 10Option Exercise1.0040,91240,91280,812Aug 11 08:03 PM
Dubensky Thomas W.Chief Scientific OfficerAug 10Sale11.4340,912467,66539,900Aug 11 08:03 PM
SCHAFER GREGORY WChief Operating OfficerAug 08Option Exercise1.2714,18918,004135,168Aug 09 07:45 PM
SCHAFER GREGORY WChief Operating OfficerAug 08Sale12.1614,189172,550120,979Aug 09 07:45 PM
Lew JenniferSr. Vice President of FinanceAug 07Option Exercise0.826,6005,41249,195Aug 09 07:41 PM
Brockstedt Dirk G.EVP of Research and Dev.Aug 07Option Exercise0.5210,0005,20059,300Aug 09 07:44 PM
SCHAFER GREGORY WChief Operating OfficerAug 07Option Exercise1.2225,81131,616146,790Aug 09 07:45 PM
ISAACS STEPHEN TPresident and CEOAug 07Option Exercise0.4540,00018,000144,025Aug 09 07:46 PM
ISAACS STEPHEN TPresident and CEOAug 07Sale12.1940,000487,564104,025Aug 09 07:46 PM
SCHAFER GREGORY WChief Operating OfficerAug 07Sale12.1725,811314,233120,979Aug 09 07:45 PM
Brockstedt Dirk G.EVP of Research and Dev.Aug 07Sale12.1810,000121,79549,300Aug 09 07:44 PM
Lew JenniferSr. Vice President of FinanceAug 07Sale12.176,60080,29042,595Aug 09 07:41 PM